LLY | Eli lilly and company - Stock Value & PE Ratio Analysis

3

24

15

Limited Growth

AI analysis rates LLY with a lower value score of 2.
It is mainly due to unstable operating cash flow, along with potential higher debt.
Over the past 3 months, LLY has maintained a consecutive value rating of 2.0, slightly lower than the rating of 3.3 over the past 3 years, indicating slight decrease in enterprise value.
Compared to all stocks in the Health Care sector, LLY has a medium value rating.

LLY Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/05/03 (Weekly Update)

LLY Financial Forecast

Unit : USD

Update to 2025/5/4 (Quarterly Update)

LLY Earnings Table

Unit : USD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	3.34	29.5%	2.5%	12.73B	45.2%	0.5%	32.6%
2024Q3	5.32	113.7%	-2.4%	13.53B	44.7%	0.4%	8.5%
2024Q2	1.18	1,080%	-19.7%	11.44B	20.4%	-5.4%	26.3%
2024Q1	3.92	85.8%	50.8%	11.3B	36%	13.2%	25.6%
2023Q4	2.58	59.3%	4.9%	8.77B	26%	-1.9%	23.4%

Update to 2025/5/7 (Quarterly Update)

LLY Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

LLY Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of LLY from 2007/01 till Now

2603.45%
Cumulative Return: 19.73%
Annual Return: 24.26%
Volatility: 0.81
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from January, 2007 to May, 2025. (Total Trades: 3)